Medivation Shares Almost Double in Early Trading on Positive Drug Result

Medivation Inc. (MDVN) almost doubled in early trading after saying that a trial of the company’s prostate cancer drug has been halted and the medicine will be given to all participants.

Medivation surged to $32 at 7:33 a.m. The trial’s monitoring committee made the recommendation after seeing interim results, the San Francisco-based company and partner Astellas Pharma Inc. (4503) said in a statement today.

To contact the reporter on this story: Bruce Rule in New York at brule1@bloomberg.net

To contact the editor responsible for this story: Bruce Rule at brule1@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.